Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies

Esanex Inc.25 enrolled

Overview

Hsp90 is a chemical in the body that is involved in the promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Hematologic Neoplasms

Interventions

SNX-5422DRUG

dose escalated; tablets every other day; undetermined duration until disease progression

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * \>18 years old * Karnofsky performance status \> 60 * confirmed hematological malignancy * refractory to available therapy or for which no therapy is available * adequate hepatic, renal and hematological function Exclusion Criteria: * CNS malignancy * at risk for prolonged QT interval * significant GI/liver disease * other serious concurrent illness or medical condition

Locations (4)

Pfizer Investigational Site

Augusta, Georgia, United States

Pfizer Investigational Site

Chapel Hill, North Carolina, United States

Pfizer Investigational Site

Pittsburgh, Pennsylvania, United States

Pfizer Investigational Site

Nashville, Tennessee, United States

Outcomes

Primary Outcomes

adverse events and other safety assessments

Time frame: continuous

Secondary Outcomes

disease response specific to the hematological malignancy

Time frame: after every 2 cycles

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.